C5 Complement Inhibitors Drug Market By Drug Type (Monoclonal Antibodies, RNAi-based Therapies, Small Molecules & Novel Modalities); By Route of Administration (Intravenous, Subcutaneous, Oral Administration [Pipeline]); By Indication (PNH, aHUS, gMG, Neurological & Renal Disorders [Pipeline], Other Neurological and Renal Autoimmune Disorders); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

C5 Complement Inhibitors Drug Market: Market Intelligence Snapshot (Last Updated on: June-2026)

The Global C5 Complement Inhibitors Drug Market is valued at USD 9.8 billion in 2024 and projected to reach USD 16.7 billion by 2030, expanding at a strong 9.3% CAGR.

 

The C5 complement inhibitors drug market is a specialty biologics market built around therapies that block terminal complement activation. These drugs bind to complement protein C5 or reduce C5 production, preventing cleavage into C5a and C5b and stopping downstream membrane attack complex formation. Approved therapies are used in rare, immune-mediated, and complement-driven diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, and CHAPLE disease.

 

This is not a high-volume generic market. Commercial value depends on rare-disease diagnosis, biomarker or antibody confirmation, long-term therapy duration, infection-risk management, dosing convenience, and specialty reimbursement. Future growth is moving toward longer-acting antibodies, subcutaneous administration, RNAi-based C5 reduction, and competition between established C5 blockade and newer upstream complement pathways.

 

Patient Pool and Eligible Treatment Base

The C5 complement inhibitors drug market is driven by rare-disease eligibility rather than broad patient volume. PNH remains one of the core commercial indications, with estimated prevalence reported up to about 15.9 people per million worldwide. Atypical hemolytic uremic syndrome adds another high-value indication, with published prevalence estimates around 4.9 to 5.0 cases per million people. These diseases are small in population size but commercially important because patients often require long-term complement control.

Neurology has become the second major expansion area. Myasthenia gravis affects roughly 150 to 200 people per million globally, but the C5-eligible population is narrower because approved use is concentrated in generalized myasthenia gravis patients with acetylcholine receptor antibody-positive disease. NMOSD is also highly selective, with studies reporting prevalence in single-digit to low-teens per 100,000 population depending on race and geography, and approximately three-quarters of NMOSD patients testing positive for AQP4-IgG in some cohorts.

CHAPLE disease creates the smallest approved commercial niche. Fewer than 100 patients have been diagnosed worldwide, but the disease is clinically important because CD55 deficiency causes uncontrolled complement activation, protein-losing enteropathy, edema, malnutrition, infections, and potentially life-threatening complications. The treated pool for C5 inhibitors is therefore shaped by confirmed diagnosis, antibody status, complement-mediated disease activity, breakthrough symptoms, infusion or injection burden, and payer approval.

 

Approved Drugs and Clinical Trial Landscape

Approved C5 inhibitors include eculizumab, ravulizumab, zilucoplan, pozelimab, and crovalimab. Eculizumab, marketed as Soliris by Alexion/AstraZeneca, is a humanized monoclonal antibody that binds C5 and prevents its cleavage into C5a and C5b. It established the C5 inhibitor category across PNH, aHUS, generalized myasthenia gravis, and NMOSD.

Ravulizumab, marketed as Ultomiris by Alexion/AstraZeneca, is a long-acting C5 monoclonal antibody engineered from eculizumab. Its commercial advantage is reduced infusion frequency, which supports patient convenience and long-term adherence in chronic rare diseases. Zilucoplan, marketed as Zilbrysq by UCB, is a subcutaneous macrocyclic peptide C5 inhibitor approved for AChR antibody-positive generalized myasthenia gravis. Pozelimab, marketed as Veopoz by Regeneron, is a fully human monoclonal antibody targeting C5 and is approved for CHAPLE disease.

Crovalimab, marketed as Piasky by Roche/Genentech and Chugai, should be treated as an approved drug rather than only a clinical-stage asset. It is a C5 monoclonal antibody designed for pH-dependent recycling and subcutaneous maintenance dosing in PNH, creating a convenience-driven competitive signal against established infusion-based C5 therapies.

The clinical-trial landscape is focused on longer durability, alternative delivery, and C5 production suppression. Cemdisiran from Alnylam and Regeneron is an RNAi therapeutic designed to reduce C5 production in the liver. It represents a different approach from monoclonal antibody C5 blockade and is being evaluated in complement-mediated diseases including generalized myasthenia gravis.

 

Disease Confirmation and Treatment Eligibility

C5 inhibitor use depends on confirmed complement-mediated disease and indication-specific eligibility. In PNH, treatment decisions are linked to flow-cytometry confirmation of PNH clones, hemolysis markers, transfusion burden, symptoms, thrombosis risk, and breakthrough hemolysis. In aHUS, eligibility depends on thrombotic microangiopathy features and exclusion of alternative causes.

In generalized myasthenia gravis, antibody status is commercially important because C5 inhibitors are positioned mainly in AChR antibody-positive disease. In NMOSD, anti-AQP4 antibody positivity defines the eligible complement-mediated population. For CHAPLE disease, genetic and clinical confirmation of CD55-deficient protein-losing enteropathy defines the treated pool.

 

Treatment Selection, Sequencing, and Safety Constraints

C5 inhibitors are chronic, high-risk specialty therapies where product choice depends on disease control, dosing burden, route of administration, and infection-risk management. In PNH and aHUS, treatment selection is driven by hemolysis control, thrombotic or kidney-risk reduction, transfusion burden, breakthrough complement activity, and prior exposure to eculizumab or ravulizumab. In gMG and NMOSD, treatment choice depends on antibody status, relapse risk, symptom severity, prior immunotherapy, and specialist assessment.

Dosing convenience is now a real competitive factor. Eculizumab established the class but requires frequent intravenous maintenance dosing. Ravulizumab reduces infusion frequency and supports longer-interval chronic therapy. Zilucoplan adds a subcutaneous self-administered option for AChR antibody-positive generalized myasthenia gravis, while crovalimab adds subcutaneous maintenance dosing in PNH. These differences matter because many eligible patients remain on therapy for years.

Safety is central to the category. C5 inhibition increases susceptibility to serious meningococcal infection, so vaccination, patient education, infection monitoring, and risk-management requirements are part of the treatment infrastructure. This does not weaken the market; it explains why C5 inhibitors remain specialist-driven therapies rather than routine broad-use immunology drugs.

 

Specialty Access and Branded Therapy 

C5 complement inhibitors are premium rare-disease biologics. Access depends on specialist diagnosis, indication-specific documentation, antibody or complement-disease confirmation, vaccination compliance, prior therapy history, and payer authorization. Because treated populations are small and therapy duration can be long, commercial value is driven by eligible-patient identification, retention on therapy, dosing convenience, and label expansion rather than high prescription volume.

Competition is shifting from first-in-class complement blockade toward lower treatment burden and better patient fit. Eculizumab created the original C5 market, while ravulizumab improved convenience through longer-interval dosing. Zilucoplan and crovalimab add subcutaneous administration advantages in selected indications, and cemdisiran represents a different approach by reducing C5 production through RNA interference.

The market’s branded economics are therefore shaped by chronic rare-disease use, infusion versus subcutaneous delivery, payer confidence, specialist familiarity, and the ability to maintain complement control without increasing treatment burden. This makes C5 inhibitors a high-value specialty market where convenience, safety infrastructure, and documented eligibility are as important as clinical efficacy.

 

Market Leaders

Key companies shaping the C5 complement inhibitors drug market include Alexion/AstraZeneca, UCB, Regeneron Pharmaceuticals, Roche/Genentech, Chugai Pharmaceutical, Alnylam Pharmaceuticals, Amgen, and other complement-focused biotechnology companies.

Alexion/AstraZeneca remains the category leader through Soliris and Ultomiris. UCB adds neurology-focused C5 competition through zilucoplan. Regeneron is relevant through pozelimab and cemdisiran development with Alnylam. Roche and Chugai bring competitive pressure through crovalimab in PNH, especially where subcutaneous administration and recycling antibody design improve convenience.

 

Competitive Signals

Recent market signals show that the C5 inhibitor market is becoming more competitive and more delivery-focused. Crovalimab’s approval in PNH added a subcutaneous maintenance option and increased pressure on established infusion-based C5 therapies. Ravulizumab’s expansion into AQP4 antibody-positive NMOSD strengthened long-acting C5 blockade in neurology.

Pipeline signals also point toward mechanism diversification. Cemdisiran’s RNAi approach aims to reduce C5 production rather than only bind circulating C5. This matters commercially because future competition may be shaped by durability, administration route, patient convenience, and ability to control breakthrough complement activity.

 

Growth Outlook

The C5 complement inhibitors drug market will remain a premium rare-disease biologics category. Growth will depend on label expansion, earlier diagnosis, route-of-administration improvements, biosimilar and branded competition, and the ability to manage long-term infection risk.

C5 inhibitors are no longer defined only by first-in-class complement blockade. They are becoming a competition between established antibodies, longer-acting biologics, self-administered options, and RNAi-based C5 reduction.

 

C5 Complement Inhibitors Drug Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 9.8 Billion
Revenue Forecast in 2030	USD 16.7 Billion
Overall Growth Rate	CAGR of 9.3% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Drug Type, By Route of Administration, By Indication, By Region
By Drug Type	Monoclonal Antibodies, RNAi-based Therapies, Small Molecules & Novel Modalities
By Route of Administration	Intravenous, Subcutaneous, Oral Administration (Pipeline)
By Indication	PNH, aHUS, gMG, Neurological & Renal Disorders (Pipeline), Other Neurological and Renal Autoimmune Disorders
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, Japan, China, India, Brazil, Saudi Arabia, etc.
Market Drivers	Expansion into Neurology, Long-acting and RNAi Innovations, Rising Rare Disease Awareness
Customization Option	Available upon request